Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE)

Kurzeder, Christian; Bover, Isabel; Marmé, Frederik; Rau, Joern; Pautier, Patricia; Colombo, Nicoletta; Lorusso, Domenica; Ottevanger, Petronella; Bjurberg, Maria; Marth, Christian; Barretina-Ginesta, Pilar; Vergote, Ignace; Floquet, Anne; Del Campo, Josep M; Mahner, Sven; Bastière-Truchot, Lydie; Martin, Nicolas; Oestergaard, Mikkel Z; Kiermaier, Astrid; Schade-Brittinger, Carmen; Polleis, Sandra; du Bois, Andreas; Gonzalez-Martin, Antonio

doi:10.1200/JCO.2015.66.0787

Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE)

Author:

Kurzeder, Christian

Bover, Isabel ; Marmé, Frederik ; Rau, Joern ; Pautier, Patricia ; Colombo, Nicoletta ; Lorusso, Domenica ; Ottevanger, Petronella ; Bjurberg, Maria ; Marth, Christian ; Barretina-Ginesta, Pilar ; Vergote, Ignace ; Floquet, Anne ; Del Campo, Josep M ; Mahner, Sven ; Bastière-Truchot, Lydie ; Martin, Nicolas ; Oestergaard, Mikkel Z ; Kiermaier, Astrid ; Schade-Brittinger, Carmen ; Polleis, Sandra ; du Bois, Andreas ; Gonzalez-Martin, Antonio

Keywords:

Science & Technology, Life Sciences & Biomedicine, Oncology, METASTATIC BREAST-CANCER, FALLOPIAN-TUBE CANCER, PRIMARY PERITONEAL, BEVACIZUMAB, TRASTUZUMAB, DOCETAXEL, COMBINATION, GEMCITABINE, CARBOPLATIN, DOXORUBICIN, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Double-Blind Method, Drug Resistance, Neoplasm, Female, Humans, Middle Aged, Ovarian Neoplasms, RNA, Messenger, Receptor, ErbB-3, Receptor, erbB-3, 1103 Clinical Sciences, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, 3211 Oncology and carcinogenesis

Abstract:

The AGO-OVAR 2.29/ENGOT-ov14/PENELOPE prospectively randomized phase III trial evaluated the addition of pertuzumab to chemotherapy in patients with platinum-resistant ovarian carcinoma with low tumor human epidermal growth factor receptor 3 (HER3) mRNA expression. We report the results of the primary efficacy analysis.